Stoke Therapeutics, Inc.

NASDAQ:STOK

Biotechnology

Healthcare
$26.69 -1.12%

-$0.34 today

Market cap
$1.75B
Beta
1.19
P/E (TTM)
-11.1
EPS (TTM)
-$2.69
52W Low $11.17High $40.22

Volume 0.76M

Average 0.64M

STOK Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Stoke Therapeutics, Inc.NASDAQ: STOK

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows in line with its trailing trend

Q1 FY2026 selling, general & admin of $19.97M rose 36.3% year over year, ahead of the +35.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 2.5% from the prior quarter. Over 3 fiscal years it compounded at +19.9% a year.

Context

  • Selling, general & admin amounted to 36.4% of revenue in FY2025, down 97.1 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 9 analysts of $74.8M (+11.5%) for the fiscal year ending Dec 2026, a slowdown from the +37.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.97M-2.5% QoQ
Last fiscal yearDec 2025
$67.09M+37.5% YoY
LTMMar 2026
$71.21M+35.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+36.3%-32.4%-68.8 pp
1 year+37.5%+11.5%-26.0 pp
3-year CAGR+19.9%+62.4%+42.5 pp
5-year CAGR+80.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
67.09M USD
Year-over-year change
+37.5%
4-year CAGR
+20.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How STOK compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +35.2% is the 2nd highest of 6, against a peer median of +14.0%.
  • Selling, general & admin amounts to 222.0% of revenue for STOK, versus a peer median of 106.6%.
STOK Competitors
Selling, General & Admin for STOK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$584.98M USD+66.3%+37.9%61.0%
BEAMBeam Therapeutics Inc.LTM Jun 2026$125.4M USD+14.0%+9.0%80.4%
WVEWave Life Sciences Ltd.LTM Mar 2026$79.08M USD+23.9%+14.3%110.1%
STOKStoke Therapeutics, Inc.LTM Mar 2026$71.21M USD+35.2%+19.9%222.0%
SLNSilence Therapeutics plcLTM Mar 2026$23.59M USD—+2.2%2560.2%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$20.62M USD+11.6%+2.3%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€14.33M EUR+6.6%-8.9%106.6%
Peer median (excluding STOK) —+14.0%+5.7%106.6%

Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue012.41M8.78M36.56M184.42M
Cost of Revenue00000
Gross Profit012.41M8.78M36.56M184.42M
Gross Margin—100.0%100.0%100.0%100.0%
Research & Development54.17M77.84M82.23M89.13M137.92M
Selling, General & Admin31.9M38.92M41.32M48.79M67.09M
Operating Expenses86.07M116.76M123.55M137.93M205.01M
Depreciation & Amortization974K1.55M2.47M2.18M1.77M
EBITDA(84.83M)(99.52M)(102.23M)(86.8M)(5.12M)
EBITDA Margin—-802.3%-1164.4%-237.5%-2.8%
Operating Income(86.07M)(104.36M)(114.77M)(101.37M)(20.59M)
Operating Margin—-841.2%-1307.2%-277.3%-11.2%
Interest Income120K3.12M9.91M12.64M13.77M
Interest Expense00009K
Other Income / Expenses260K3.29M10.07M12.39M13.71M
Income Before Tax(85.81M)(101.07M)(104.7M)(88.98M)(6.89M)
Pre-Tax Margin—-814.7%-1192.5%-243.4%-3.7%
Income Tax Expense00000
Net Income(85.81M)(101.07M)(104.7M)(88.98M)(6.89M)
Net Margin—-814.7%-1192.5%-243.4%-3.7%
EPS (Basic)(2.34)(2.60)(2.38)(1.65)(0.12)
EPS (Diluted)(2.34)(2.60)(2.38)(1.65)(0.12)
Weighted Avg Shares36.74M38.9M43.99M54.01M59.22M
Weighted Avg Shares (Diluted)36.74M38.9M43.99M54.01M59.22M

Stoke Therapeutics, Inc.

NASDAQ:STOK

Intrinsic Alpha fair value

Locked

Current Price

$26.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.